A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Inclusion Criteria: * Patients with first ST elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset * Diagnosis of STEMI requires the presence of the following three criteria: * Typical clinical symptoms such as chest pain, shortness of breath for more than 20 minutes related to the myocardial infarction * New ST elevation indicating myocardial infarction * Significant elevation in troponin T or I with at least one value above the 99th percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and creatine kinase MB (6-10% of total CK) * At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45% and an infarct size \>10% LV mass (as measured by LGE-MRI, central-blinded evaluation) Exclusion Criteria: * Contraindication to perform contrast-enhanced cardiac MRI * LVEF \< 20% * History of heart failure or LVEF \< 50% before occurrence of the first STEMI * Infarct size \> 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction * NYHA (New York Heart Association) class IV at randomization * Any planned cardiac intervention after baseline MRI or any other planned operations * Non-ischemic causes for cardiomyopathy * Diagnosis of atrial fibrillation * Systolic blood pressure \< 100 mm Hg or \> 180 mm Hg; diastolic blood pressure \< 50 mm Hg or \>110 mm Hg, heart rate \< 50 or \>100 beat/minute; mean of triplicate values at randomization * Clinically relevant hepatic dysfunction